Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients

Blood Purification

Volumn 24, Issue 5-6, 2006, Pages 508-516

  Kaysen, George A ^a,b,c   Levin, Nathan W ^d   Mitch, William E ^e   Chapman, Anna L P ^a,b   Kubala, Lukas ^a,b   Eiserich, Jason P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Biochemistry and Molecular Medicine ^*  (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d RENAL RESEARCH INSTITUTE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Myeloperoxidase; Oxidative stress; Soluble intercellular adhesion molecule; Vascular endothelial growth factor

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENZYME; INTERLEUKIN 6; LEUKOCYTE DERIVED MYELOPEROXIDASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTERIOVENOUS FISTULA; ARTICLE; CARDIOVASCULAR RISK; CATHETER; CELL ADHESION; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845964765     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096471     Document Type: Article

References (34)

1. Ridker PM, Buring JE, Shih J, et al: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-733.
2. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-476.
3. Ockene IS, Matthews CE, Rifai N, et al: Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-450.
4. Kaysen GA, Dubin JA, Muller, et al: The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int 2000;58:346-352.
5. Zimmermann J, Herrlinger S, Pruy A, et al: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
6. Bologa RM, Levine DM, Parker TS, et al: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-114.
7. Yeh ET: CRP as a mediator of disease. Circulation 2004;109(suppl 1):11-14.
8. Libby P: Inflammation in atherosclerosis. Nature 2002;420:868-874.
9. Daugherty A, Dunn JL, Rateri DL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444.
10. Zhang R, Brennan ML, Fu X, Aviles et al., Sprecher DL, Hazen SL: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-2142.
11. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int 2003;84:172-176.
12. Kutter D, Devaquet P, Vanderstocken G, et al: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 2000;104:10-15.
13. Baldus S, Heeschen C, Meinertz T, et al: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445.
14. Lemström KB, Krebs R, Nykänen, et al: Vascular endothelial growth factor enhances cardiac allograft atherosclerosis. Circulation 2002;105:2524-2530.
15. Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T, Yamamoto K, Kato T, Ono Y, Nagata M, Hayakawa N, Suzuki A, Goto Y, Oda N: The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004;53:550-555.
16. Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, et al: Vascular endothelial growth factor in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000;17:650-656.
17. Asselbergs FW, de Boer RA, Diercks GF, Langeveld B, Tio RA, de Jong PE, van Veldhuisen DJ, van Gilst WH: Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004;93:211-215.
18. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY: Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 2001;87:805-807.
19. Eiserich JP, Baldus S, Brennan, et al: Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296:2391-2394.
20. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J: Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997;90:4153-4161.
21. Taichman NS, Young S, Cruchley AT, Taylor P, Paleolog E: Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol 1997;62:397-400.
22. Dowton SB, Waggoner DJ, Mandl KD: Developmental regulation of expression of Creactive protein and serum amyloid A in Syrian hamsters. Pediatr Res 1991;30:444-449.
23. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G: Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 1989;8:3773-3779.
24. Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
25. Baldus S, Eiserich JP, Mani A, et al: Endothelial transcytosis of myeloperoxidase confers specificity to ECM proteins as targets of tyrosine nitration. J Clin Invest 2001;108:1759-1770.
26. Rattazzi M, Puato M, Faggin E, et al: C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003;21:1787-1803.
27. Doherty DG, O'Farrelly C: Innate and adaptive lymphoid cells in the human liver. Immunol Rev 2000;174:5-20.
28. Schoneveld AH, Oude Nijhuis MM, van Middelaar B, Laman JD, de Kleijn DP, Pasterkamp G: Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res 2005;66:162-169.
29. Mittermayer F, Pleiner J, Schaller G, et al: Marked increase in vascular endothelial growth factor concentrations during Escherichia coli endotoxin-induced acute inflammation in humans. Eur J Clin Invest 2003;33:758-761.
30. Roy-Chaudhury P, Kelly BS, Miller MA, et al: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001;59:2325-2334.
31. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
32. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J: Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881-900.
33. Filep J, Foldes-Filep E: Effects of C-reactive protein on human neutrophil granulocytes challenged with N-formyl-methionyl- leucylphenylalanine and platelet-activating factor. Life Sci 1989;44:517-524.
34. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-2618.